Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a note issued to investors on Saturday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and issued a $5.00 target price on shares of Minerva Neurosciences in a research note on Wednesday, February 26th.

Minerva Neurosciences Stock Up 5.2 %

Shares of NASDAQ NERV opened at $1.60 on Friday. The stock’s 50-day simple moving average is $1.66 and its two-hundred day simple moving average is $2.08. Minerva Neurosciences has a twelve month low of $1.15 and a twelve month high of $3.69. The firm has a market capitalization of $11.19 million, a P/E ratio of -3.64 and a beta of -0.09.

Minerva Neurosciences (NASDAQ:NERV) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($1.05) by $0.49. As a group, research analysts anticipate that Minerva Neurosciences will post -0.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of NERV. Citadel Advisors LLC boosted its stake in shares of Minerva Neurosciences by 49.5% in the 4th quarter. Citadel Advisors LLC now owns 25,764 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 8,525 shares in the last quarter. Northern Trust Corp boosted its position in Minerva Neurosciences by 60.0% during the fourth quarter. Northern Trust Corp now owns 36,878 shares of the biopharmaceutical company’s stock valued at $82,000 after buying an additional 13,829 shares during the period. Finally, Apella Capital LLC bought a new position in shares of Minerva Neurosciences during the first quarter valued at about $35,000. 34.56% of the stock is currently owned by institutional investors.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.